TY - JOUR
T1 - Interactions among myeloid regulatory cells in cancer
AU - Umansky, Viktor
AU - Adema, Gosse J.
AU - Baran, Jaroslaw
AU - Brandau, Sven
AU - Van Ginderachter, Jo A.
AU - Hu, Xiaoying
AU - Jablonska, Jadwiga
AU - Mojsilovic, Slavko
AU - Papadaki, Helen A.
AU - Pico de Coaña, Yago
AU - Santegoets, Kim C.M.
AU - Santibanez, Juan F.
AU - Serre, Karine
AU - Si, Yu
AU - Sieminska, Isabela
AU - Velegraki, Maria
AU - Fridlender, Zvi G.
N1 - Publisher Copyright:
© 2018, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2019/4/2
Y1 - 2019/4/2
N2 - Mounting evidence has accumulated on the critical role of the different myeloid cells in the regulation of the cancerous process, and in particular in the modulation of the immune reaction to cancer. Myeloid cells are a major component of host cells infiltrating tumors, interacting with each other, with tumor cells and other stromal cells, and demonstrating a prominent plasticity. We describe here various myeloid regulatory cells (MRCs) in mice and human as well as their relevant therapeutic targets. We first address the role of the monocytes and macrophages that can contribute to angiogenesis, immunosuppression and metastatic dissemination. Next, we discuss the differential role of neutrophil subsets in tumor development, enhancing the dual and sometimes contradicting role of these cells. A heterogeneous population of immature myeloid cells, MDSCs, was shown to be generated and accumulated during tumor progression as well as to be an important player in cancer-related immune suppression. Lastly, we discuss the role of myeloid DCs, which can either contribute to effective anti-tumor responses or play a more regulatory role. We believe that MRCs play a critical role in cancer-related immune regulation and suggest that future anti-cancer therapies will focus on these abundant cells.
AB - Mounting evidence has accumulated on the critical role of the different myeloid cells in the regulation of the cancerous process, and in particular in the modulation of the immune reaction to cancer. Myeloid cells are a major component of host cells infiltrating tumors, interacting with each other, with tumor cells and other stromal cells, and demonstrating a prominent plasticity. We describe here various myeloid regulatory cells (MRCs) in mice and human as well as their relevant therapeutic targets. We first address the role of the monocytes and macrophages that can contribute to angiogenesis, immunosuppression and metastatic dissemination. Next, we discuss the differential role of neutrophil subsets in tumor development, enhancing the dual and sometimes contradicting role of these cells. A heterogeneous population of immature myeloid cells, MDSCs, was shown to be generated and accumulated during tumor progression as well as to be an important player in cancer-related immune suppression. Lastly, we discuss the role of myeloid DCs, which can either contribute to effective anti-tumor responses or play a more regulatory role. We believe that MRCs play a critical role in cancer-related immune regulation and suggest that future anti-cancer therapies will focus on these abundant cells.
KW - Dendritic cells
KW - Macrophages
KW - Mye-EUNITER
KW - Myeloid regulatory cells
KW - Myeloid-derived suppressor cells
KW - Neutrophils
UR - http://www.scopus.com/inward/record.url?scp=85049801577&partnerID=8YFLogxK
U2 - 10.1007/s00262-018-2200-6
DO - 10.1007/s00262-018-2200-6
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 30003321
AN - SCOPUS:85049801577
SN - 0340-7004
VL - 68
SP - 645
EP - 660
JO - Cancer Immunology, Immunotherapy
JF - Cancer Immunology, Immunotherapy
IS - 4
ER -